Aromatase mRNA expression in individual follicles from polycystic ovaries.
Polycystic ovary syndrome (PCOS) is a common reproductive disorder characterized by arrested follicular development prior to selection of a dominant follicle. Dominant follicles produce large amounts of oestradiol but PCOS follicles do not. With several potential aromatase (P450AROM) inhibitors in follicular fluid, the question arises whether P450AROM is expressed in PCOS granulosa cells, but the activity is inhibited, or whether P450AROM is not expressed in PCOS. The purpose of the present study was to determine whether P450AROM mRNA expression is altered in PCOS and to correlate P450AROM mRNA expression in individual follicles with aromatase stimulatory bioactivity and oestradiol in the follicular microenvironments. P450AROM mRNA was measured in individual follicles from 16 PCOS and 48 regularly cycling control women by quantitative polymerase chain reaction (PCR) and correlated with follicular fluid oestradiol concentrations and aromatase stimulating bioactivity measured by the rat granulosa cells aromatase bioassay. Follicular fluid oestradiol was low in all control follicles <7 mm in diameter. Some follicles > or = 7 mm contained elevated oestradiol values (P < 0.01) and all had an androstenedione:oestradiol ratio of <4. Only in granulosa cells from follicles > or = 7 mm with an androstenedione:oestradiol ratio of <4 were P450AROM mRNA levels increased (P < 0.05). These same follicles also contained increased levels of aromatase stimulating bioactivity whereas follicles <7 mm or with androstenedione:oestradiol ratio of >4 contained little or no bioactivity. All PCOS follicles contained low levels of oestradiol, P450AROM mRNA and aromatase stimulating bioactivity similar to size-matched control follicles. These data indicate that P450AROM mRNA expression and oestradiol production begin in developing follicles when they reach approximately 7 mm in diameter. Oestradiol production is low in PCOS follicles because there is insufficient aromatase stimulating bioactivity to increase P450AROM mRNA expression.
Jakimiuk
A J
AJ
Department of Obstetrics and Gynecology, Second Clinic of Surgical Gynecology, University School of Medicine, Lublin, Poland.
Weitsman
S R
SR
Brzechffa
P R
PR
Magoffin
D A
DA
D000735:Androstenedione / Q000032:analysis; D000818:Animals; D001141:Aromatase / Q000235:genetics*; D004958:Estradiol / Q000032:analysis; D005260:Female; D015571:Follicular Fluid / Q000737:chemistry / Q000201:enzymology; D005498:Follicular Phase; D015971:Gene Expression Regulation, Enzymologic / Q000502:physiology*; D006107:Granulosa Cells; D006801:Humans; D010053:Ovary / Q000166:cytology / Q000378:metabolism*; D011085:Polycystic Ovary Syndrome / Q000201:enzymology / Q000378:metabolism*; D016133:Polymerase Chain Reaction / Q000379:methods; D012333:RNA, Messenger / Q000032:analysis*; D051381:Rats; D017207:Rats, Sprague-Dawley
D012333:RNA, Messenger; D000735:Androstenedione; D004958:Estradiol; D001141:Aromatase